Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC11FCD therapy in recurrent glioblastoma (dose-finding, safety, and preliminary efficacy)
KCT0005886Phase 2Recruiting
- Sponsor
- CELLeBRAIN
- Start
- Mar 2021
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of MSC11FCD in glioblastoma (GBM), sponsored by CELLeBRAIN. Started Mar 2021; status: recruiting.
02
Drugs
MSC11FCD
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on KCT0005886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005886.